more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$65.96 USD

+1.38 (2.14%)

Updated May 10, 2024 04:00 PM ET

After-Market: $65.92 -0.04 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Research for GILD

Annual Key Company Metrics
Quarterly Key Company Metrics

Revenue - Line of Business Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: Vemlidy: Total [$M...		862	842	814	657	488
Product Sales: Yescarta: Total [$...		1,498	1,160	695	563	456
Revenue share: Symtuza: Total [$M...		529	530	531	--	--
Revenues: Sofosbuvir / Velpatasvi...		1,537	1,530	1,462	1,599	1,965
Product Sales: Other HIV Total [$...		56	57	195	407	--
Product Sales: Other Hepatitis C ...		160	166	207	193	--
Product Sales: Tecartus: Total [$...		370	299	176	44	--
Revenues: Other Product: Total [$...		225	253	281	276	--
Revenues: Product: Tecartus: Othe...		15	3	0	--	--
Total Liver Disease: Total [$M]		2,784	2,798	2,850	--	--
Total Oncology: Total [$M]		2,932	2,139	1,251	--	--
Revenues: Product sales [$M]		26,934	26,982	27,008	24,355	22,119
Revenues: Royalty contract and ot...		182	299	297	334	330
Product Sales: AmBisome [$M]		492	497	540	436	407
Product Sales: HIV: Truvada [$M]		114	147	371	1,448	2,813
Product Sales: Hepatitis B virus ...		83	91	111	185	243
Product Sales: Letairis [$M]		142	196	206	1,376	2,640
Product Sales: Other [$M]		859	946	1,027	136	214
Revenues: Complera / Eviplera: To...		129	200	258	269	406
Revenues: Stribild: Total [$M]		101	127	189	196	369
Antiviral products: Ledipasvir/So...		70	115	212	272	643
Product Sales: Total HIV [$M]		18,175	17,194	16,315	16,938	16,438
Product Sales: Total HCV [$M]		1,767	1,810	1,881	2,064	2,936
Product Sales: Total Hepatitis B ...		1,017	988	969	860	--
Product Sales: Cell therapy: Tota...	--	1,869	1,459	871	601	--
Product Sales: Trodelvy: Total [$...		1,063	680	380	49	--
Product Sales: Total Veklury [$M]		2,184	3,905	5,565	2,811	--
Product Sales: Biktarvy: Total [$...		11,850	10,390	8,624	7,259	4,738
Product Sales: Descovy: Total [$M...		1,985	1,872	1,700	1,861	1,500
Product Sales: Genvoya: Total [$M...		2,060	2,404	2,879	3,338	3,931
Product Sales: Odefsey: Total [$M...		1,350	1,469	1,568	1,672	1,655
Revenue - Geographic Segments	YR Estimate	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Product Sales: Genvoya: Europe [$...		205	284	391	490	664
Product Sales: Genvoya: Other Int...		103	136	221	243	283
Product Sales: Descovy: Europe [$...		100	118	164	197	255
Product Sales: Odefsey: Europe [$...		294	364	440	450	438
Product Sales: Vemlidy: U.S [$M]		410	429	384	356	309
Product Sales: Vemlidy: Europe [$...		38	35	34	29	21
Product Sales: Vemlidy: Other Int...		414	379	396	272	158
Product Sales: Yescarta: U.S [$M]		811	747	406	362	373
Revenue share: Symtuza: Europe [$...		133	168	165	159	130
Product Sales: Veklury: U.S [$M]		972	1,575	3,640	2,026	--
Product Sales: Veklury: Europe [$...		408	702	1,095	607	--
Product Sales: Veklury: Other Int...		805	1,628	830	178	--
Product Sales: Total HCV: Europe ...	--	378	413	421	414	742
Product Sales: Total HCV: Other I...	--	386	392	442	562	729
Revenues: Sofosbuvir / Velpatasvi...	--	859	844	815	864	971
Revenues: Sofosbuvir / Velpatasvi...		323	355	316	337	553
Revenues: Sofosbuvir / Velpatasvi...		355	331	331	398	441
Product Sales: Biktarvy: Europe [...		1,253	1,103	969	735	--
Product Sales: Biktarvy: Other In...		905	777	606	429	--
Product Sales: Descovy: Other Int...		114	123	139	138	--
Product Sales: Odefsey: Other Int...		44	47	52	50	--
Product Sales: Other HIV: U.S [$M...		37	15	136	332	--
Product Sales: Other HIV: Europe ...		12	24	30	26	--
Product Sales: Other HIV: Other I...		7	17	29	49	--
Product Sales: Other Hepatitis C ...		104	115	119	132	--
Product Sales: Other Hepatitis C ...	--	43	40	74	48	--
Product Sales: Other Hepatitis C ...	--	12	10	14	13	--
Product Sales: Total Hepatitis B ...		418	435	397	380	--
Product Sales: Total Hepatitis B ...	--	133	112	104	409	--
Product Sales: Total Hepatitis B ...	--	466	441	468	409	--
Product Sales: Tecartus: U. S [$M...		245	221	136	34	--
Product Sales: Tecartus: Europe [...		110	75	40	10	--
Product Sales: Yescarta: Europe [...		547	355	253	191	--
Product Sales: Yescarta: Other In...		140	57	36	10	--
Product Sales: Cell therapy: U. S...		1,055	968	542	396	--
Product Sales: Cell therapy: Euro...		658	430	293	201	--
Product Sales: Cell therapy: Othe...		156	60	36	10	--
Product Sales: Trodelvy: U. S [$M...		777	525	370	380	--
Product Sales: Trodelvy: Europe [...		217	143	10	--	--
Product Sales: Trodelvy: Other In...		68	12	--	--	--
Product Sales: AmBisome: U.S. [$M...		43	57	39	61	--
Product Sales: AmBisome: Europe [...		260	258	274	230	--
Product Sales: AmBisome: Other In...		189	182	227	145	--
Revenues: Other Product: Other: U...		118	135	136	176	--
Revenues: Other Product: Other: E...		40	65	115	84	--
Revenues: Other Product: Other: O...		66	53	30	16	--
Revenue share: symtuza: Other int...		13	14	11	--	--
Revenues: Product-Other HBV/HDV(6...	--	72	55	42	--	--
Total Liver Disease: US [$M]		1,421	1,440	1,415	--	--
Total Liver Disease: Europe [$M]		511	525	525	--	--
Total Liver Disease: Other Intern...		852	833	910	--	--
Total Oncology: US [$M]		1,833	1,494	912	--	--
Total Oncology: Europe [$M]		875	573	303	--	--
Total Oncology: Other Internation...		224	73	36	--	--
Product Sales: HIV: Truvada: Euro...		13	15	22	27	101
Product Sales: HIV: Truvada: Othe...		19	18	35	45	2,813
Product Sales: HIV: Viread: US [$...		8	6	11	8	32
Product Sales: Hepatitis B virus ...	--	22	23	28	34	69
Product Sales: Hepatitis B virus ...	--	52	62	72	137	142
Product Sales: Total HIV: Europe ...		2,102	2,219	2,366	2,287	2,312
Product Sales: Total HIV: Other i...		1,226	1,155	1,121	1,000	811
Product Sales: U.S. [$M]		19,377	18,716	19,176	18,141	16,565
Product Sales: Europe [$M]		4,197	4,342	4,678	3,894	3,567
Product Sales: Other Internationa...		3,361	3,924	3,154	2,320	1,987
Revenues: Complera / Eviplera: Eu...		70	113	142	159	214
Revenues: Complera / Eviplera: Ot...		12	13	14	21	32
Revenues: Stribild: Europe [$M]		21	29	43	54	75
Revenues: Stribild: Other Interna...		8	10	14	17	26
Antiviral products: Harvoni /Ledi...		39	46	84	92	312
Antiviral products: Harvoni /Ledi...	--	12	17	31	29	71
Antiviral products: Harvoni /Ledi...	--	19	51	97	151	260
Product Sales: Biktarvy: U.S [$M]		9,692	8,510	7,049	6,095	4,225
Product Sales: Descovy: U.S [$M]		1,771	1,631	1,397	1,526	1,078
Product Sales: Genvoya: U.S [$M]		1,752	1,983	2,267	2,605	2,984
Product Sales: Odefsey: U.S [$M]		1,012	1,058	1,076	1,172	1,180
Revenue share: Symtuza: U.S [$M]		382	348	355	331	249
Revenues: Complera / Eviplera: Un...		47	74	102	89	160
Revenues: Stribild: United States...		72	88	132	125	268
Product Sales: HIV: Truvada: U.S....		82	113	314	1,376	2,640
Product Sales: Total HIV: US [$M]		14,848	13,820	12,828	13,651	13,315
Product Sales: Total HCV: U.S [$M...		1,002	1,005	1,018	1,088	1,465

Revenue - Line of Business Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Product Sales: Vemlidy: Total [$M...		225	217	228	219	199
Product Sales: Yescarta: Total [$...		380	368	391	380	359
Revenue share: Symtuza: Total [$M...		141	139	131	120	138
Revenues: Sofosbuvir / Velpatasvi...		405	378	377	397	385
Product Sales: Other HIV Total [$...		117	15	13	20	9
Product Sales: Other Hepatitis C ...		38	37	38	40	45
Product Sales: Tecartus: Total [$...		100	98	96	88	89
Revenues: Other Product: Total [$...		80	54	65	53	51
Revenues: Product: Tecartus: Othe...		8	5	4	4	3
Total Liver Disease: Total [$M]		737	691	706	711	675
Total Oncology: Total [$M]		789	765	769	728	670
Revenues: Product sales [$M]		6,647	7,070	6,994	6,564	6,306
Revenues: Royalty contract and ot...		39	45	56	35	46
Product Sales: AmBisome [$M]		144	111	115	151	116
Product Sales: HIV: Truvada [$M]		--	18	22	42	32
Product Sales: Hepatitis B virus ...		--	21	21	21	19
Product Sales: Letairis [$M]		--	36	36	40	32
Product Sales: Other [$M]		--	201	216	243	199
Revenues: Complera / Eviplera: To...		--	24	34	32	39
Revenues: Stribild: Total [$M]		27	22	25	26	28
Antiviral products: Ledipasvir/So...		--	17	23	15	15
Product Sales: Total HIV [$M]		4,342	4,693	4,667	4,626	4,190
Product Sales: Total HCV [$M]		--	432	438	452	445
Product Sales: Total Hepatitis B ...		426	259	269	259	230
Product Sales: Cell therapy: Tota...		480	466	486	469	448
Product Sales: Trodelvy: Total [$...		309	299	283	260	222
Product Sales: Total Veklury [$M]		555	720	636	256	573
Product Sales: Biktarvy: Total [$...		2,946	3,109	3,085	2,979	2,677
Product Sales: Descovy: Total [$M...		426	509	511	516	449
Product Sales: Genvoya: Total [$M...		403	517	503	540	501
Product Sales: Odefsey: Total [$M...		310	340	343	351	317
Revenue - Geographic Segments	Qtr Estimate	03/31/2024	12/31/2023	09/30/2023	06/30/2023	03/31/2023
Product Sales: Genvoya: Europe [$...		49	48	47	56	55
Product Sales: Genvoya: Other Int...		21	22	23	29	29
Product Sales: Descovy: Europe [$...		26	25	25	25	25
Product Sales: Odefsey: Europe [$...		76	71	74	74	76
Product Sales: Vemlidy: U.S [$M]		95	115	112	96	87
Product Sales: Vemlidy: Europe [$...		11	10	9	10	9
Product Sales: Vemlidy: Other Int...		119	92	106	113	103
Product Sales: Yescarta: U.S [$M]		170	187	197	217	210
Revenue share: Symtuza: Europe [$...		33	32	32	33	36
Product Sales: Veklury: U.S [$M]		315	364	258	97	252
Product Sales: Veklury: Europe [$...		70	181	65	52	111
Product Sales: Veklury: Other Int...		--	175	313	107	209
Product Sales: Total HCV: Europe ...	--	--	84	85	95	114
Product Sales: Total HCV: Other I...	--	--	97	93	98	99
Revenues: Sofosbuvir / Velpatasvi...		248	216	215	223	204
Revenues: Sofosbuvir / Velpatasvi...		79	74	76	84	90
Revenues: Sofosbuvir / Velpatasvi...		78	89	85	90	90
Product Sales: Biktarvy: Europe [...		365	333	313	302	304
Product Sales: Biktarvy: Other In...		265	188	268	237	212
Product Sales: Descovy: Other Int...		26	28	26	31	29
Product Sales: Odefsey: Other Int...		11	11	11	11	11
Product Sales: Other HIV: U.S [$M...		60	13	10	10	4
Product Sales: Other HIV: Europe ...		45	1	3	7	1
Product Sales: Other HIV: Other I...		57	1	--	3	3
Product Sales: Other Hepatitis C ...		59	25	28	28	24
Product Sales: Other Hepatitis C ...	--	9	10	7	9	18
Product Sales: Other Hepatitis C ...	--	21	3	3	3	4
Product Sales: Total Hepatitis B ...		371	119	116	97	86
Product Sales: Total Hepatitis B ...	--	26	37	34	35	26
Product Sales: Total Hepatitis B ...	--	29	103	119	127	117
Product Sales: Tecartus: U. S [$M...		55	66	64	56	59
Product Sales: Tecartus: Europe [...		36	27	27	29	27
Product Sales: Yescarta: Europe [...		158	140	154	133	121
Product Sales: Yescarta: Other In...		52	42	40	30	28
Product Sales: Cell therapy: U. S...		225	253	261	272	269
Product Sales: Cell therapy: Euro...	--	195	167	181	162	148
Product Sales: Cell therapy: Othe...		60	46	45	34	31
Product Sales: Trodelvy: U. S [$M...		206	226	201	189	162
Product Sales: Trodelvy: Europe [...		68	48	62	53	54
Product Sales: Trodelvy: Other In...		36	24	21	17	6
Product Sales: AmBisome: U.S. [$M...		14	4	12	20	6
Product Sales: AmBisome: Europe [...		70	68	63	69	60
Product Sales: AmBisome: Other In...		60	39	39	61	49
Revenues: Other Product: Other: U...		59	28	34	26	30
Revenues: Other Product: Other: E...		9	9	9	10	12
Revenues: Other Product: Other: O...		12	17	23	17	9
Revenue share: symtuza: Other int...		4	3	3	3	4
Revenues: Product-Other HBV/HDV(6...	--	23	22	19	7	11
Total Liver Disease: US [$M]		385	370	376	356	318
Total Liver Disease: Europe [$M]		137	121	119	131	140
Total Liver Disease: Other Intern...		215	200	211	225	217
Total Oncology: US [$M]		431	479	462	462	431
Total Oncology: Europe [$M]		262	216	243	215	202
Total Oncology: Other Internation...		96	70	65	51	37
Product Sales: HIV: Truvada: Euro...		5	3	3	3	3
Product Sales: HIV: Truvada: Othe...		6	3	4	7	5
Product Sales: HIV: Viread: US [$...		2	4	4	1	-1
Product Sales: Hepatitis B virus ...	--	7	6	5	6	6
Product Sales: Hepatitis B virus ...	--	16	12	12	14	14
Product Sales: Total HIV: Europe ...		596	533	519	521	528
Product Sales: Total HIV: Other i...		342	261	341	326	298
Product Sales: U.S. [$M]		--	5,180	4,985	4,777	4,434
Product Sales: Europe [$M]		--	1,128	1,017	999	1,053
Product Sales: Other Internationa...		--	762	992	788	819
Revenues: Complera / Eviplera: Eu...		--	15	18	16	22
Revenues: Complera / Eviplera: Ot...		--	3	3	3	3
Revenues: Stribild: Europe [$M]		--	5	5	5	6
Revenues: Stribild: Other Interna...		--	2	2	2	2
Antiviral products: Harvoni /Ledi...		--	11	17	8	3
Antiviral products: Harvoni /Ledi...	--	--	1	2	2	7
Antiviral products: Harvoni /Ledi...	--	--	5	4	5	5
Product Sales: Biktarvy: U.S [$M]		2,315	2,588	2,504	2,439	2,161
Product Sales: Descovy: U.S [$M]		371	457	460	460	395
Product Sales: Genvoya: U.S [$M]		332	447	433	455	417
Product Sales: Odefsey: U.S [$M]		223	258	257	267	230
Revenue share: Symtuza: U.S [$M]		104	104	96	84	98
Revenues: Complera / Eviplera: Un...		--	6	13	13	14
Revenues: Stribild: United States...		--	15	18	19	20
Product Sales: HIV: Truvada: U.S....		19	12	15	32	23
Product Sales: Total HIV: US [$M]		3,405	3,899	3,807	3,778	3,364
Product Sales: Total HCV: U.S [$M...		--	251	260	259	232

Member Sign In

Member Sign In

Services Overview

Investor Services

Other Services

Trading Services

Innovators